Borje S. Andersson MD

Hematologic Oncology

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Andersson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Andersson's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
Karolinska Institute Faculty of MedicineClass of 1977

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TX State Medical License 1983 - 2028
IA State Medical License 1982 - 1984
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis Start of enrollment: 2011 Mar 17
ACTIVE_NOT_RECRUITING
PHASE2

Publications & Presentations

PubMed

Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Uday R Popat, Konstantinos Lontos, Roland Bassett, Jitesh Kawedia, Ben C Valdez
Transplantation and Cellular Therapy. 2026-10-01
1 citations
A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia.
Rongrong Liu, Hongwen Xiao, Chunjie Qin, Jiong Hu, Jianming Luo
Nature Communications. 2026-02-23
1 citations
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.
Yago Nieto, John F Ward, Wayne Hofstetter, David Rice, Jose A Karam
Clinical Cancer Research. 2026-01-16

Journal Articles

Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...
Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Abstracts/Posters

Decitabine As Part of a Modified Bu-Cy Conditioning Regimen Significantly Improved the Outcome of High-Risk AML Patients Undergoing Allogeneic Hematopoietic Stem Cell ...
Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Borje S Andersson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Non-Hodgkin’s Lymphoma Survivor: MD Anderson Saved My Life Three TimesAugust 19th, 2019
Your Stem Cell Transplant Consultation: Questions to AskJanuary 25th, 2017
Best of Cancerwise 2016: Our Experts’ Most Helpful InsightDecember 27th, 2016